AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, January 6, 2021

Information

Tags:

Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa

Geotags:

Alachua, FL, Us, FLA

Organisation:

APPLIED GENETIC TECHNOLOGIES CORPORATION

Summary

Key Points:

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Virtual BioConnect Conference held January 11 – 14, 2021.

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS:
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
[email protected] or [email protected]

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
[email protected]

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected]